PBEInvesco Biotechnology & Genome ETF

Grow my money20y track recordRanked #1,269 of 2,960 in this goal

Seeks to track the investment results of the Dynamic Biotech & Genome Intellidex Index.

By Invesco · Launched 2005

Annual Cost

0.58%

#2,930 of 5,562 · average

Fund Size

$259M

#2,091 of 5,562 · mid-size

Return (1Y)Goal

+32.4%

Track Record

20 years

#232 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$14,484+44.8%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

Dynamic Biotech & Genome Intellidex Index

What it actually holds

By weight

Concentration

Top 10 holdings = 53.7% of fundmoderately concentrated

Invesco Private Prime Fund

10.2%

Illumina, Inc.

5.7%

Gilead Sciences, Inc.

5.6%

Amgen Inc.

5.1%

Biogen Inc.

5.0%

United Therapeutics Corp.

4.9%

Regeneron Pharmaceuticals, Inc.

4.8%

Incyte Corp.

4.7%

Invesco Private Government Fund

3.9%

Amicus Therapeutics, Inc.

3.9%

Asset allocation

Stocks

100.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

19.0%Moderate

Year-on-year price swings

Max drawdown

-37.8%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.43Below average

Sortino (3Y)

0.62Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks to track the investment results of the Dynamic Biotech & Genome Intellidex Index.
Strategy: Invests at least 90% of total assets in securities of the Dynamic Biotech & Genome Intellidex Index, which includes common stocks of 30 U.S. biotechnology and genome companies. Employs full replication methodology to track the index.
Inception date: June 23, 2005
Fund family: Invesco